Market news

Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock

Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences. 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 Fireside Chat at

Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering

Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker outlined the company’s rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright’s 6th Annual Ophthalmology Investor Conference, emphasizing the company’s focus on Frizzled-4 signaling, anti-VEGF activity and,

Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026...